Breaking News, Collaborations & Alliances

Ascentage Pharma Receives $100M Option Payment from Takeda

Is eligible for an option exercise fee and additional potential milestone payments of up to approximately $1.2B and royalties on annual sales.

Author Image

By: Charlie Sternberg

Associate Editor

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, has received the $100 million option payment in relation to the Exclusive Option Agreement with Takeda for the third-generation BCR-ABL inhibitor olverembatinib (HQP1351). On June 14, 2024, Ascentage Pharma and Takeda entered into an Exclusive Option Agreement that granted Takeda an exclusive option to ente...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters